CA2539814C - Isoquinolinone potassium channel inhibitors - Google Patents

Isoquinolinone potassium channel inhibitors Download PDF

Info

Publication number
CA2539814C
CA2539814C CA2539814A CA2539814A CA2539814C CA 2539814 C CA2539814 C CA 2539814C CA 2539814 A CA2539814 A CA 2539814A CA 2539814 A CA2539814 A CA 2539814A CA 2539814 C CA2539814 C CA 2539814C
Authority
CA
Canada
Prior art keywords
substituted
group
methoxy
hydrogen
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2539814A
Other languages
English (en)
French (fr)
Other versions
CA2539814A1 (en
Inventor
B. Wesley Trotter
Christopher Claiborne
Gerald S. Ponticello
Charles J. Mcintyre
Nigel Liverton
David A. Claremon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2539814A1 publication Critical patent/CA2539814A1/en
Application granted granted Critical
Publication of CA2539814C publication Critical patent/CA2539814C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2539814A 2003-09-23 2004-09-17 Isoquinolinone potassium channel inhibitors Expired - Fee Related CA2539814C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50510103P 2003-09-23 2003-09-23
US60/505,101 2003-09-23
PCT/US2004/030431 WO2005030791A2 (en) 2003-09-23 2004-09-17 Isoquinolinone potassium channel inhibitors

Publications (2)

Publication Number Publication Date
CA2539814A1 CA2539814A1 (en) 2005-04-07
CA2539814C true CA2539814C (en) 2010-07-06

Family

ID=34392976

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2539814A Expired - Fee Related CA2539814C (en) 2003-09-23 2004-09-17 Isoquinolinone potassium channel inhibitors

Country Status (7)

Country Link
US (2) US7723352B2 (OSRAM)
EP (1) EP1667982B1 (OSRAM)
JP (1) JP4718467B2 (OSRAM)
CN (1) CN1856476A (OSRAM)
AU (1) AU2004276236B2 (OSRAM)
CA (1) CA2539814C (OSRAM)
WO (1) WO2005030791A2 (OSRAM)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2539541C (en) * 2003-09-23 2010-06-29 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
CA2539729C (en) * 2003-09-23 2010-09-07 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
WO2005030791A2 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
US7709476B2 (en) * 2003-09-23 2010-05-04 Merck Sharp & Dohme Corp. Isoquinolinone potassium channel inhibitors
AU2004276268B2 (en) * 2003-09-23 2009-01-29 Merck Sharp & Dohme Corp. Isoquinoline potassium channel inhibitors
US7723290B2 (en) 2004-10-22 2010-05-25 Bioincept, Llc Compositions and methods for modulating the immune system
WO2006015159A2 (en) 2004-07-29 2006-02-09 Merck & Co., Inc. Potassium channel inhibitors
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
DE102005028862A1 (de) * 2005-06-22 2007-01-11 Sanofi-Aventis Deutschland Gmbh Substituierte Heterocyclen, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
WO2007000240A1 (en) 2005-06-28 2007-01-04 Sanofi-Aventis Isoquinoline derivatives as inhibitors of rho-kinase
UA93882C2 (ru) 2005-07-26 2011-03-25 Санофи-Авентис Пиперидинил-замещенные производные изохинолона kak ингибиторы rho-киназы
JP5049970B2 (ja) 2005-07-26 2012-10-17 サノフイ Ｒｈｏ−キナーゼ阻害剤としてのシクロヘキシルアミンイソキノロン誘導体
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
EP1989197A1 (en) * 2006-02-17 2008-11-12 Janssen Pharmaceutica, N.V. Pyrazolylquinazolinones as potassium channel openers
NZ577980A (en) 2006-12-27 2012-01-12 Sanofi Aventis Cycloalkylamine substituted isoquinolone derivatives
KR101545533B1 (ko) 2006-12-27 2015-08-19 사노피 치환된 이소퀴놀린 및 Ｒｈｏ-키나아제 억제제로서의 이의 용도
WO2008077552A1 (en) 2006-12-27 2008-07-03 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives
WO2008077556A1 (en) 2006-12-27 2008-07-03 Sanofi-Aventis Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives
DE602007013950D1 (de) * 2006-12-27 2011-05-26 Sanofi Aventis Cycloalkylaminsubstituierte isochinolon- und isochinolinonderivate
JP5405316B2 (ja) 2006-12-27 2014-02-05 サノフイ シクロアルキルアミン置換イソキノリン誘導体
MY150746A (en) 2006-12-27 2014-02-28 Sanofi Aventis Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
CN103432133B (zh) 2007-01-22 2016-08-10 Gtx公司 核受体结合剂的用途
HUE026617T2 (en) 2008-06-24 2016-06-28 Sanofi Sa Substituted isoquinolines and isoquinolinones as RHO kinase inhibitors
WO2009156099A1 (en) 2008-06-24 2009-12-30 Sanofi-Aventis 6-substituted isoquinolines and isoquinolinones
ES2434121T3 (es) 2008-06-24 2013-12-13 Sanofi Derivados de isoquinolina e isoquinolinona bi- y policíclicos sustituidos como inhibidores de rho cinasa
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
EP2680872B1 (en) 2011-03-02 2018-08-15 BioIncept LLC Use of pif peptides for treating infections, atherosclerosis and peritonitis
WO2013142390A1 (en) * 2012-03-21 2013-09-26 Gtx, Inc. Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
HRP20200341T1 (hr) * 2013-10-18 2020-06-12 Celgene Quanticel Research, Inc. Bromodomenski (bet) inhibitori
EA038715B1 (ru) * 2014-01-24 2021-10-08 Селджен Квонтисел Рисёрч, Инк. Ингибиторы бромодомена
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
US11096987B2 (en) 2015-08-28 2021-08-24 Bioincept, Llc Mutant peptides and methods of treating subjects using the same
EP3341006A4 (en) 2015-08-28 2019-03-13 BioIncept LLC COMPOSITIONS AND METHODS FOR TREATING NERVE DAMAGE
AU2017252276A1 (en) 2016-04-18 2018-11-15 Celgene Quanticel Research, Inc. Therapeutic compounds
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
EP4126819A1 (en) * 2020-04-03 2023-02-08 Vertex Pharmaceuticals Incorporated 7- or 8-hydroxy-isoquinoline and 7- or 8-hydroxy-quinoline derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3594380A (en) * 1969-02-18 1971-07-20 American Home Prod Isoquinolin-1(2h)-ones
US3878215A (en) * 1971-12-01 1975-04-15 Sandoz Ag 2-Alkyl-3-substituted-4-aryl isoquinolines
US4897391A (en) * 1988-06-17 1990-01-30 Schering Corporation Tricyclic anti-allergy, antiinflammatory and anti-hyperproliferative compounds
NO179904C (no) * 1992-09-04 1997-01-08 Takeda Chemical Industries Ltd Kondenserte heterocykliske forbindelser og deres anvendelse
US5728712A (en) * 1995-05-19 1998-03-17 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
DE60132606T2 (de) 2000-09-20 2009-02-19 Merck & Co., Inc. Isochinolinone als kalium-kanal-inhibitoren
EP1396488A1 (en) 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
CA2476162A1 (en) * 2002-02-13 2003-08-21 Takeda Chemical Industries, Ltd. Jnk inhibitor
CA2539541C (en) * 2003-09-23 2010-06-29 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
WO2005030791A2 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
CA2539729C (en) * 2003-09-23 2010-09-07 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
AU2004276268B2 (en) * 2003-09-23 2009-01-29 Merck Sharp & Dohme Corp. Isoquinoline potassium channel inhibitors
US7709476B2 (en) * 2003-09-23 2010-05-04 Merck Sharp & Dohme Corp. Isoquinolinone potassium channel inhibitors

Also Published As

Publication number Publication date
WO2005030791A3 (en) 2005-05-26
EP1667982A2 (en) 2006-06-14
CN1856476A (zh) 2006-11-01
EP1667982B1 (en) 2013-07-31
US20070027177A1 (en) 2007-02-01
EP1667982A4 (en) 2008-08-13
US8338449B2 (en) 2012-12-25
US7723352B2 (en) 2010-05-25
JP4718467B2 (ja) 2011-07-06
AU2004276236A1 (en) 2005-04-07
US20100256698A1 (en) 2010-10-07
CA2539814A1 (en) 2005-04-07
AU2004276236B2 (en) 2008-01-24
JP2007516218A (ja) 2007-06-21
WO2005030791A2 (en) 2005-04-07

Similar Documents

Publication Publication Date Title
CA2539814C (en) Isoquinolinone potassium channel inhibitors
CA2539707C (en) Quinoline potassium channel inhibitors
AU2004289186B2 (en) Isoquinolinone potassium channel inhibitors
CA2539479C (en) Isoquinoline potassium channel inhibitors
CA2539541C (en) Isoquinolinone potassium channel inhibitors
AU2004276268B2 (en) Isoquinoline potassium channel inhibitors
CA2539760C (en) Quinoline potassium channel inhibitors
CA2539729C (en) Isoquinolinone potassium channel inhibitors
WO2006028590A1 (en) 1,1,2,2-tetra (hetero) arylethanes or 1,1,2-tri (hetero) aryl-2-heterocyclylethanes as potassium channel inhibitors

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150917